Key Insights:
- Cantor Fitzgerald rates Harrow (HROW, Financial) as Overweight with a bullish $76 price target.
- Analysts predict a potential upside of 63.54% from the current price.
- Harrow is poised to lead in the U.S. ophthalmology market with strategic investments.
Harrow (HROW) recently captured investor attention after its shares climbed 11%, following an Overweight rating from Cantor Fitzgerald. The investment firm underscored a bright outlook for Harrow, setting an ambitious price target of $76. This optimism is rooted in Harrow’s strategic positioning to become a leader in the U.S. ophthalmology market, buoyed by its ventures into Melt Pharmaceuticals and the development of its key product, MELT?300, for sedation in cataract surgeries.
Wall Street Analysts Forecast
Investors are eyeing Harrow Inc (HROW, Financial) with keen interest as the one-year price targets provided by six analysts reveal an average target price of $55.87. This range includes a high estimate of $65.00 and a low estimate of $42.00. The average target price suggests an impressive 63.54% potential upside from the current trading price of $34.16. For more nuanced data, visit the Harrow Inc (HROW) Forecast page.
Harrow Inc (HROW, Financial) garners an "Outperform" status based on consensus from seven brokerage firms, reflected through an average brokerage recommendation of 1.6 on a scale where 1 indicates a Strong Buy and 5 signals a Sell.
According to GuruFocus estimates, the GF Value of Harrow Inc (HROW, Financial) for the next year is projected at $42.43. This represents a 24.21% upside compared to the current price of $34.1601. The GF Value is a proprietary metric that estimates a stock's fair value by analyzing its historical trading multiples, past business growth, and projected business performance. More detailed insights can be accessed on the Harrow Inc (HROW) Summary page.
